To evaluate the onset timing of musculoskeletal adverse events (MAEs) that develop during statin monotherapy and to determine whether concomitant drugs used concurrently with statin therapy shifts the onset timing of MAEs. Cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and pravastatin) were prescribed were extracted from the US Food and Drug Adminis- 
of atherosclerotic cardiovascular disease (ASCVD). 1, 2 However, if musculoskeletal adverse events (MAEs) such as myalgia, myopathy, and rhabdomyolysis develop during the statin use period, these cholesterol-lowering treatments may need to be temporarily or permanently discontinued. 2 There are a few reports detailing the onset timing of drug-induced adverse events. 3, 4 In 2004, Chang et al reported the onset timing of statin-induced rhabdomyolysis. 5 However, the difference in onset timing of rhabdomyolysis between each statin was not detected owing to few number of cases.
It is difficult to detect drug-drug interactions (DDIs) that may cause severe adverse events at the stage of drug approval examination. 6 DDIs are usually discovered during postmarketing surveillance. 7, 8 It is already known that the concomitant use of statins and specific nonstatin drugs increases the risk of rhabdomyolysis.
For example, the concomitant use of statins with fibrates [9] [10] [11] or cytochrome P450 (CYP) inhibitors, such as clarithromycin (CYP3A4 inhibitor), cyclosporine (CYP3A4 inhibitor), and clopidogrel (CYP2C8 inhibitor), increases the risk of rhabdomyolysis. [12] [13] [14] It has been reported that the increased risk of statin-induced rhabdomyolysis may be due to the pharmacokinetic changes caused by concomitant drugs. 15 If DDIs cause changes in the time-course of blood concentration of statins, it not only changes the onset risk, but may also affect the onset timing. There are limited studies evaluating the risk of concomitant drugs on the onset timing of statin adverse events.
To reduce and prevent the risk of adverse events in a clinical setting, it is important to acquire information on both the risk and onset timing of drug-induced adverse events. We have already evaluated the onset timing of adverse events as well as the risk of these events. 3, 16 Although many drugs have the potential to cause the same adverse event, especially those within the same medication class, the onset timing of these events for individual drugs may differ; thus, it is important to evaluate the onset timing of side effects associated with each drug.
The Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) is often used to detect DDIs. Risk evaluation using disproportionality is performed to determine these DDIs. 17, 18 Although the incidence of statin-induced MAEs differs in literature, statins are well-tolerated and rarely cause MAEs. Therefore, the incidence of statin-induced MAEs is very low, 11, 19, 20 and it is difficult to evaluate the onset timing of statin-induced MAEs through clinical trials as these adverse events may occur within 12 months of starting statin therapy or after many years. 10 Since clinical trials are performed only for a specific period, postmarketing surveillance and reporting of adverse events through FAERS is helpful to determine the onset timing of MAEs. The FAERS is a large-scale database that accumulates reported cases of adverse events; thus, it is suitable for analysing MAEs that develop at a low frequency during statin use.
Therefore, this study was aimed at investigating the onset timing of MAEs in cases using statin monotherapy and if concomitant drugs shifted the onset timing of MAEs. 
| MATERIALS AND METHODS

| Data sources
| Definition of MAEs
The following events were considered as MAEs based on a previous report 21 taken from the Medical Dictionary for Regulatory Activities (MedDRA, version 20.1) at the Preferred Term level: "rhabdomyolysis"
(MedDRA code 10039020), "myalgia" (10028411), "myoglobinuria"
(10028629), and "blood creatine phosphokinase increased" (10005470).
| Standardisation of names of drugs reported to FAERS
The drugs reported to FAERS can be registered by arbitrary names, including trade names and typographical errors. 22 Therefore, we used DRUGBANK (version 5.0.11) to standardise the names of drugs, including statins and other concomitant drugs. 
| Statistical analysis
Cases of statin monotherapy were collected and a nonparametric method, the Steel-Dwass test, was used to determine if the time-toonset of MAEs differed by statin type. This nonparametric analysis method was adopted as it was assumed that the time-to-onset would not be normally distributed. To determine if concomitant drugs affected the time-to-onset of statin-induced MAEs, paired comparisons between cases of each concomitant drug use and cases of statin monotherapy were also performed using the Steel test.
All statistical analyses were performed using R software (version 3.2.2, R Foundation for Statistical Computing, Vienna, Austria) for
The significance level (P) was set at 0.05. 
| RESULTS
| Time-to-onset of MAEs in cases of statin monotherapy
| Onset timing of MAEs by statin type
The maximum number of cases of MAE onset was associated with atorvastatin, followed by rosuvastatin and simvastatin, and the num- The magnitude of HMG-CoA reductase 50% inhibitory concentration (IC 50 ) for each statin was in the order of rosuvastatin < atorvastatin < simvastatin < fluvastatin < pravastatin. 24 Atorvastatin or rosuvastatin, which possesses a high HMG-CoA reductase inhibitory activity, is considered high-intensity statin therapy that reduces LDL cholesterol by more than 50%. The use of the other statins is considered either moderate or low-intensity statin therapy. 1 Hoffman et al reported the following order for the relative risk of statin-induced MAEs: rosuvastatin > atorvastatin > simvastatin > pravastatin > lovastatin. 25 These indicate that the higher the HMG-CoA reductase inhibitory activity (or the lower the IC 50 ) of a statin, the higher the relative risk of MAEs tends to be. Previous study findings and the results of the present study suggest that statins with a high HMGCoA reductase inhibitory activity, such as atorvastatin and rosuvastatin, not only increase the onset risk of MAEs, but also induce MAEs within a short time.
We also considered the relationship between statin lipophilicity and MAE onset timing. Rosuvastatin and pravastatin are known to have very low lipophilicity than other statins (in descending order:
simvastatin > fluvastatin > atorvastatin > rosuvastatin > pravastatin). 24 Statin lipophilicity does not correlate with the relative risk of statin-induced MAEs nor the MAE onset timing for any statin. 
| Effects of concomitant drugs on the onset timing of MAEs
This study also investigated whether concomitant drugs used concurrently with statins impacted the onset timing of MAEs. The results
showed that concomitant drugs in all statin-concomitant drug combinations evaluated in this study did not affect the onset timing of MAEs.
Atorvastatin is mainly metabolised by CYP3A4 and partially by CYP2C8. 28, 29 Similar to atorvastatin, 1,4-dihydropyridine calcium channel blockers such as amlodipine are metabolised by CYP3A4; therefore, the MAE onset risk may increase because of DDI. 30 However, the blood concentration is not greatly affected, and the effect is not clinically significant. 31 Similar to amlodipine, diltiazem is metabolised by CYP3A4, and the MAE onset risk may increase. 30, 32 Nevertheless, the concomitant use of atorvastatin and diltiazem did not cause changes in the onset timing of MAEs (Table 2) .
Simvastatin is mostly metabolised by CYP3A4, while some of it is metabolised by CYP2C8. 33, 34 It has been known that the concomitant use of simvastatin and amlodipine increases the risk of myopathy. 35, 36 In addition, the concomitant use of simvastatin and cyclosporine is contraindicated as cyclosporine inhibits CYP3A4. 37 However, these drugs did not cause changes in the onset timing of MAEs.
Thus, it was clarified that even if the concomitant use of statins and drugs that may cause DDI can change the MAE onset risk, it is unlikely that the onset timing will be changed. The results also showed that it is unlikely for other concomitant drugs, which are thought to have no drug interaction with statins, to cause changes in the onset timing of MAEs. The Steel test was performed for cases of the simvastatin monotherapy group (n = 409) as the control group. IQR, interquartile range; MAEs, musculoskeletal adverse events. to the time-to-onset for MAEs, the dosage must be taken into consideration. However, in cases reported to FAERS, data regarding administration and dosage are often missing; thus, the statin dosage of each case could not be taken into consideration. Hence, the changes in onset timing of MAEs dependent on statin dosage could not be evaluated in this study.
| Limitations
